FLT
Les inhibiteurs de la tyrosine kinase FLT (Fms-like) sont des composés qui ciblent les récepteurs FLT, impliqués dans la régulation de l'angiogenèse via la voie du VEGF (facteur de croissance endothélial vasculaire). Les récepteurs FLT jouent un rôle crucial dans le développement de nouveaux vaisseaux sanguins dans les tumeurs. L'inhibition des récepteurs FLT peut réduire efficacement l'angiogenèse et la croissance tumorale, ce qui rend ces inhibiteurs importants en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une sélection d'inhibiteurs de FLT de haute qualité pour soutenir vos recherches en oncologie, biologie vasculaire et angiogenèse.
88 produits trouvés pour "FLT"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
MRX-2843
CAS :MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).Formule :C29H40N6ODegré de pureté :98.59% - 99.63%Couleur et forme :SolidMasse moléculaire :488.67Ref: TM-T16144
1mg62,00€5mg138,00€10mg215,00€25mg430,00€50mg622,00€100mg887,00€1mL*10mM (DMSO)148,00€FLT3-IN-3
CAS :FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.Formule :C27H38N8ODegré de pureté :99.25%Couleur et forme :SolidMasse moléculaire :490.64Ref: TM-T11298
1mg107,00€5mg259,00€10mg432,00€25mg715,00€50mg1.008,00€100mg1.359,00€500mg2.717,00€1mL*10mM (DMSO)278,00€FLT3/HDAC-IN-2
Compound 25h, also known as FLT3/HDAC-IN-2, is a dual inhibitor of FLT3/HDAC. It exhibits antiproliferative activity against MOLM-13 cells and is used in the study of acute myeloid leukemia.Couleur et forme :Odour SolidPROTAC FLT-3 degrader 3
PROTACFLT-3degrader 3 (compound 35) is a PROTAC degrader of FLT. It exhibits antiproliferative activity, with an IC50 value of 7.55 nM in MV4-11 cells.Formule :C48H44Cl2N10O6Masse moléculaire :926.28223FLT3 Ligand-Linker Conjugate 1
CAS :FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.Formule :C29H34N6O4S2Couleur et forme :SolidMasse moléculaire :594.7482-Butenamide
CAS :2-Butenamide, FLT3 inhibitor. Affordable Excellence: Reliable Quality You Can TrustFormule :C4H7NOCouleur et forme :SolidMasse moléculaire :85.1FLT3-IN-24
FLT3-IN-24 (compound 24) is a potent and selective inhibitor of FLT3 kinase, with an IC50 of 7.94 nM. It also exhibits anti-proliferative effects on cells.Formule :C23H20N6O2SMasse moléculaire :444.13685FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Formule :C29H35N7O5Couleur et forme :SolidMasse moléculaire :561.63FLT3-IN-20
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.Formule :C28H33N7O2SCouleur et forme :SolidMasse moléculaire :531.67FLT3-IN-22
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.Formule :C24H22N6O2Couleur et forme :SolidMasse moléculaire :426.47FLT3-ITD-IN-2
FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.Formule :C39H50N8O6Couleur et forme :SolidMasse moléculaire :726.86FLT3-IN-23
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effectsCouleur et forme :Odour SolidPacritinib citrate
CAS :Pacritinib (SB1518) citrate effectively inhibits wild-type JAK2 (IC 50 =23 nM) and the JAK2 V617F mutant (IC 50 =19 nM). It also targets FLT3 (IC 50 =22 nM) and the FLT3 D835Y mutant (IC 50 =6 nM). This compound is utilized in the study of acute myeloid leukemia (AML) and myelofibrosis (MF) [1] [2] [3].Formule :C34H40N4O10Couleur et forme :SolidMasse moléculaire :664.7JAK3-IN-14
CAS :JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.Formule :C18H13N3ODegré de pureté :98.29%Couleur et forme :SoildMasse moléculaire :287.32Ref: TM-T67754
1mg167,00€5mg409,00€10mg595,00€25mg888,00€50mg1.234,00€100mg1.665,00€1mL*10mM (DMSO)358,00€3-Hydroxy Midostaurin
CAS :3-Hydroxy Midostaurin (CGP 52421), a PKC412 metabolite, inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50 values of roughly 132 nM inFormule :C35H30N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.648HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Couleur et forme :Odour SolidPF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Formule :C46H50F3N13O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :969.97PF15
CAS :PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Formule :C44H49N13O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :855.94PROTAC FLT3/GSPT1/IKZF1/3 degrader-1
PROTACFLT3/GSPT1/IKZF1/3 degrader-1 is an FLT3 PROTAC degrader with DC50 = 1.2 nM. It functions as a molecular glue to degrade its brain substrates and exhibits antiproliferative activity against resistant acute myeloid leukemia (AML) cells, showing potential applications in AML research.Couleur et forme :Odour SolidEmirodatamab
CAS :Emirodatamab (AMG-427) is an anti-FLT3/CD3 bispecific T-cell engager with an extended half-life. It can induce high cytotoxicity in primary AML progenitor cells and enhance FLT-3 expression. Combining Emirodatamab with anti-PD-1 antibodies increases T-cell dependent cytotoxicity (TDCC). This compound is under investigation for use in relapsed or refractory AML.
